Endocrine therapy for advanced breast cancer: Beyond tamoxifen and aromatase inhibitors

Current Cancer Therapy Reviews

Volumn 6, Issue 1, 2010, Pages 51-61

  Guerrero Zotano, Angel ^a   Muggia, Franco ^b  

^a Medical Oncology Oncologic Institute of Valencia (IVO)   (Spain)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Androgens; Estrogens; Fulvestrant; Megestrol acetate; Progestins antagonists; Sulfatase inhibitor

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; 17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 21 METHOXY 19 NORPREGNA 4,9 DIENE 3,20 DIONE; ANASTROZOLE; ANDROGEN; ANDROSTANOLONE; ANTIGESTAGEN; AROMATASE INHIBITOR; ASOPRISNIL; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; EXEMESTANE; FLUOXYMESTERONE; FULVESTRANT; GESTAGEN; LETROZOLE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MIFEPRISTONE; OCTREOTIDE; ONAPRISTONE; PRASTERONE; PROGESTERONE; SOMATOSTATIN; TAMOXIFEN; TIPIFARNIB; TRASTUZUMAB; ULIPRISTAL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; BREAST CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ENDOMETRIOSIS; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR DEPRESSION; MENINGIOMA; MONOTHERAPY; OPTIMAL DRUG DOSE; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE DRUG DOSE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; UTERUS MYOMA; VAGINITIS;

EID: 77949889768     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410790596498     Document Type: Review

References (86)

1. Nabholtz JM, Buzdar AU, Pollak M, et al. Anastrozole is superior to Tam as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18: 3758-7.
2. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus Tam as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tam or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18: 3748-7.
3. Paridaens R, Dirix LY, Beex L, et al. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (Pts): results of a randomized phase II trial. Proc Am Soc Clin Oncol 2000; 19: 316.
4. Mouridsen HT, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus Tam as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-6.
5. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonylestra-1,3,5, (10)-triene-3,17betadiol (Faslodex) versus Tam in postmenopausal women with primary breast cancer. Cancer Res 2001; 61: 6739-6.
6. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 16: 3396-3.
7. Osborne CK, Pippen J, Jones SE, et al. Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-5.
8. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229-8.
9. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus Tam for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind randomized trial. J Clin Oncol 2004; 22: 1605-3.
10. Chia S, Gradishar W, Mauriac L, et al.Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.J Clin Oncol 2008; 26: 1664-0.
11. Robertson JF, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 2004; 90(Suppl 1): S7-S10.
12. Kuter I, Hegg R, Singer CF, et al. Fulvestrant 500 mg vs 250 mg: First results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. Breast Cancer Res Treat 106: 7; 2007 abstr 589.
13. Di Leo A, Jerusalem G, Petruzelka L, et al. CONFIRM: A phase III, Randomized, Parallel-Group trial comparing Fulvestrant 250mg vs Fulvestrant 500mg in postenopausal women with estrogen receptor positive advanced breast cancer. Cancer Res 2009; 69(Suppl.)(24): Abstract nr 25.
14. Robertson JF, Semiglazov V, Nemsadze G. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer 2007; 43: 64-7.
15. Young OE, Renshaw L, Macaskill EJ, et al. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.Eur J Cancer 2008; 44: 391-9.
16. Macedo LF, Sabnis GJ, Goloubeva OG, et al. Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft Model. Cancer Res 2008; 68: 3516-22.
17. Bergh J, Jonsson PE, Lidbrink E, et al. First result from FACT- An open label, randomized phase III study investigating loading dose of fulvestrant combined anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. Cancer Res 2009; 69(Suppl.)(24): Abstract nr 23.
18. Robertson JFR, Dixon JM, Sibbering DM, et al. Tumor biomarker changes following pre-surgical treatment with 500 mg Fulvestrant plus Anastrozole versus 500 mg Fulvestrant alone and 1 mg Anastrozole alone. Cancer Res 2009; 69(Suppl.)(24): Abstract nr 24.
19. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11: 4741-8.
20. Christos LP, Sparano JA, Hershman DL, et al. Phase II study of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor-positive breast cancer: New York Cancer Consortium Trial P6205. J Clin Oncol (Meeting Abstracts) 2007 25: 18s.
21. Pietras RJ, Marquez DC, Chen HW, et al. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat 2003; 82(suppl 1): S12.
22. Steger GG, Gips M, Simon SD, et al. Fulvestrant ('Faslodex'): Clinical experience from the Compassionate Use Programme. Cancer Treat Rev 2005; 31(suppl 2): S10-S16.
23. Robertson JF, Steger G, Neven P, Barni S. Fulvestrant in the treatment of HER2-positive advanced breast cancer (ABC). J Clin Oncol (Meeting Abstracts) 2007 25: 18s.
24. Going JJ, Anderson TJ, Battersby S, Macintyre CC. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988; 130: 193-4.
25. Michna H, Nishino Y, Schneider MR, Louton T, El Etreby MF. A bioassay for the evaluation of antiproliferative potencies of progesterone antagonists. J Steroid Biochem Mol Biol 1991; 38: 359-5.
26. Tang OS, Ho PC. Clinical applications of mifepristone.Gynecol Endocrinol 2006; 22: 655-9.
27. Belanger A, Philibert D, Teutsch G. Regio and Stereospecific synthesis of 11 beta-substituted 19-norsteroids. Infl uence of 11 betasubstitution on progesterone receptor affi nity - (1).Steroids 1981 ; 37 : 361 -82.
28. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijin M. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 1989; 125: 1593-8.
29. Robinson, S.P., and Jordan, V.C. Reversal of the antitumor effects of Tam by progesterone in the 7, 12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 1987; 47: 5386.
30. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-Mediated Mammary Tumorigenesis in Mice by a Progesterone Antagonist. Science 2006; 314: 1467-70.
31. Maudelonde T, Romieu G, Ulmann A. First clinical trial on the use of the antiprogestin RU 486 in advanced breast cancer. In Hormonal Manipulation of Cancer: Peptides, Growth Factors and New Anti-Steroidal Agents. Eds. New York: Raven Press, 1987.
32. Klij G, de Jong F, Bakker G, et al. Antiprogestins, a New Form of Endocrine Therapy for Human Breast Cancer. Cancer Res 1989; 49: 2851-6.
33. Robertson JF, Willsher PC, Winterbottom L, et al. Onapristone, a progesterone receptorantagonist, as fi rst-line therapy in primary breast cancer. Eur J Cancer 1999; 35: 214 -8.
34. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008; 111: 1129-36.
35. Williams AR, Critchley HO, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007; 22: 1696.
36. Masamura S, Santner SJ, Heitjan DF, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995; 80: 2918-2925.
37. Song RX-D, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J Natl Cancer Inst 2001; 93: 1714-23.
38. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005; 97: 1746-59.
39. Yao K, Lee ES, Bentrem DJ, et al: Antitumor action of physiological estradiol on Tam-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000; 6: 2028-36.
40. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304: 16-21.
41. Gockerman JP, Spremulli EN, Raney M, et al. Randomized comparison of Tam versus diethylstilbestrol in estrogen receptorpositive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986; 7: 1199-3.
42. Beex L, Pieters G, Smals A, et al. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 1981; 65: 179-85.
43. Peethambaram PP, Ingle JN, Suman VJ, et al. Randomized trial of diethylstilbestrol vs. Tam in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999; 54: 117-2.
44. Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001; 67: 111-16.
45. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 7: 165-70.
46. Rosenbaum E, Wygoda M, Gips M, et al. Diethylstilbestrol is an active agent in prostatic cancer patients after failure to complete androgen blockade. Proc Annl Meet Am Soc Clin Oncol. 2000; 349. Abstract 1372.
47. Ellis MJ, Dehdahti F, Kommareddy A, et al. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. SABCS 2008, Abstract 16.
48. Howell A, Dodwell DJ, Anderson H, et al. Response after withdrawal of Tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992; 3: 611-7.
49. Cigler T, Goss PE. Aromatase inhibitor withdrawal response in metastatic breast cancer J Clin Oncol 2006; 24: 1955-6.
50. Bhide SA, Rea DW. Metastatic breast cancer response after Exemestane withdrawal: A case report. Breast 2004; 13: 66-68.
51. Sasano H, Suzuki T, Miki Y, Morilla T. Intracrinology of estrogens and androgens in breast carcinoma. J Steroid Biochem Mol Biol 2008; 108: 181-185.
52. Simpson ER. Aromatization of androgens in women: current concepts and findings. Fertil Steril. 2002; 77: S6-10.
53. Honma K,Takubo M, Sawabe M, et al.Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J Clin Endocrinol Metab 2006; 91: 607-13.
54. Hall RE, Clements JA, Birrell SN, Tyllei W.Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumors. Br J Cancer 1998; 78: 360-65.
55. Moinfar F, Okeu M, Tsybrovskyy O, et al.: Androgen receptors frequently are expressed in breast carcinomas: Potential relevance to new therapeutic strategies. Cancer 2003; 98: 703-11.
56. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 1997; 193: 753-8.
57. Bryan RM, Mercer RJ, Bennett RC, Lie TH, Morgan FJ.. Androgen receptors in breast cancer. Cancer. 1984; 54: 2436-40.
58. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer, Immunohistochemical, clinical, and prognostic associations, Am J Clin Pathol 2003; 120 725-31.
59. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24: 152-82.
60. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22: 3181-6.
61. Lillie EO, Bernstein L, Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 2003; 5: 164-73.
62. Ingle JN, Twito DI, Schaid DJ, et al. Combination hormonal therapy with Tam plus fluoxymesterone versus Tam alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 1991; 67: 886.
63. ngle JN, Suman VJ, Mailliard JA, et al. Randomized trial of Tam alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006; 98: 217-22.
64. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001; 7: 1230-6.
65. Recchione C, Venturelli E, Manzari A, et al. Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol 1995; 52 541-6.
66. Morris K, Toth-Fejel S, Schmidt J, et al. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: A renewed role for adrenalectomy. Surgery 2001; 130: 947-53.
67. Stanway SJ, Delavault P, Purohit A, et al. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. The Oncologist 2007; 12: 370-4.
68. Dalm V, Hofland LJ, Lamberts S. Future clinical prospect in somatostatin/cortistatin/somatostatin receptor field. Mol Cell Endocrinol 2008; 286, 262-77.
69. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of Tam and ovariectomy on 7,12-dimethylbenz (a)anthracene-induced rat mammary carcinomas. Cancer Res 1994; 54: 6334-7.
70. Bajetta E, Procopio G, Ferrari L, et al. A randomized, multicenter prospective trial assessing longacting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 2002; 94: 299-04.
71. Ingle JN, Suman VJ, Kardinal CG, et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999; 85: 1284-92
72. Muggia FM, Cassileth PA, Ochoa M, Jr., Flatow FA, Gellhorn A, Hyman GA. Treatment of breast cancer with medroxyprogesterone acetate. Ann Int Med 1968: 328- 377, 1968.
73. Allegra JC, Kiefer SM. Mechanisms of action of progestational agents. Semin Oncol 1985; 12: 3
74. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83: 1142-52.
75. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol2000; 18: 1399-1411.
76. Buzdar A, Douma N, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001 19: 3357-66.
77. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol1998; 16: 453-61.
78. Carlini P, Bria E, Giannarelli D, et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005; 104: 1335-1342.
79. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11: 762-7.
80. Rowland KM, Loprinzi CL, Shaw EG, et al. Randomized doubleblind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996; 14: 135-41.
81. Pascualini J.R. and Chetrite G. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 2005; 93: 221-36.
82. Chetrite GS, Cortes-Prieto J, Philippe JC, et al. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Molec Biol 2000; 72: 23.
83. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer. J Clin Endocrinol Metab 1996; 81: 1460-4.
84. Miyoshi Y, Ando A, Hasegawa S, et al. High expression of steroid sulfatase mRNA predicts poor prognòsis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 2003; 9: 2288-93.
85. Stanway SJ, Purohit A, Woo LW, et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res 2006; 12: 1585-92.
86. Day JM, Tutill HJ, Purohit A, et al. Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 2008; 15: 665-92.